Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Tannock, Ian F., de Wit, Ronald, Berry, William R., Horti, Jozsef, Pluzanska, Anna, Chi, Kim N., Oudard, Stephane, Théodore, Christine +4 more·2004·New England Journal of Medicine

DOI 10.1056/nejmoa040720

Cited by (1,006)

Items 701–800 of 1,006

Giants and monsters: Unexpected characters in the story of cancer recurrence
2020 · Advances in Cancer Research
Castration-resistant prostate cancer: latest evidence and therapeutic implications
Daniel L. Suzman, Emmanuel S. Antonarakis · 2014 · Therapeutic Advances in Medical Oncology
Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial
Alexander Meisel, Stefanie von Felten, D. Vogt, Heike Liewen, Ronald de Wit, Johann Sebastian De Bono, Oliver A. Sartor, Frank Stenner · 2016 · European Journal of Cancer
Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy
Gert De Meerleer, Valérie Fonteyne, Sabine Meersschout, Caroline Van den Broecke, Geert M. Villeirs, Nicolaas Lumen, Piet Ost, Katrien Vandecasteele, Wilfried De Neve · 2008 · Radiotherapy and Oncology
Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target.
K. Ramachandran, G. Gopisetty, Edna R. Gordián, Loida Navarro, C. Hader, I. Reis, W. Schulz, R. Singal · 2009 · Cancer Research
A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies
John F. Deeken, Rebecca S. Slack, Glen J. Weiss, Ramesh K. Ramanathan, Michael Jon Pishvaian, Jimmy J. Hwang, Karen Lewandowski, Deepa Suresh Subramaniam, Aiwu Ruth He, Ion Cotarla et al. · 2012 · Cancer Chemotherapy and Pharmacology
Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone‐sensitive prostate cancer
Masaki Shiota, Masatoshi Eto · 2016 · International Journal of Urology
Predictors of Time to Metastasis in Castration-resistant Prostate Cancer
Daniel Martins Moreira, Lauren E. Howard, Katharine N. Sourbeer, Hiruni S. Amarasekara, Lydia C. Chow, Dillon C. Cockrell, Brian T. Hanyok, William J. Aronson, Christopher J. Kane, Martha K. Terris et al. · 2016 · Urology
Enhanced antitumor efficacy by cyclic RGDyK-conjugated and paclitaxel-loaded pH-responsive polymeric micelles
Yajie Gao, Yanxia Zhou, Lei Zhao, Chao Zhang, Yushu Li, Jinwen Li, Xinru Li, Yan Liu · 2015 · Acta Biomaterialia
Alkaline Phosphatase in Metastatic Castration-Resistant Prostate Cancer: Reassessment of an Older Biomarker
Daniel Alexander Heinrich, Øyvind Sverre Bruland, Theresa A. Guise, Hiroyoshi Suzuki, Oliver A. Sartor · 2018 · Future Oncology
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate‐resistant prostate cancer
Joel Picus, Susan Halabi, William Kevin Kelly, Nicholas J. Vogelzang, Young E. Whang, Ellen B. Kaplan, Walter Michael Stadler, Eric Jay Small, for Cancer and Leukemia Group B · 2010 · Cancer
Cabazitaxel Plus Prednisone for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel: Results from the German Compassionate-use Programme
Axel Heidenreich, Hans-Jörg Scholz, Sebastian Rogenhofer, Christian Arsov, Margitta M. Retz, Stefan C. Müller, Peter Albers, Jürgen E. Gschwend, Manfred Peter Wirth, Ursula Steiner et al. · 2012 · European Urology
Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
Simon Linder, Henk G. van der Poel, Andries Marinus Bergman, Wilbert T. Zwart, Stefan Preković · 2018 · Endocrine Related Cancer
Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2015
William Thomas Lowrance, Bruce J. Roth, Erin Kirkby, Mohammad Hassan Murad, Michael S. Cookson · 2015 · The Journal of Urology
Phase I/II Study of Azacitidine, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy
Rakesh Singal, Kavitha J. Ramachandran, Edna R. Gordián, Carlos Quintero, Wei K. Zhao, Isildinha Marques dos Reis · 2014 · Clinical Genitourinary Cancer
A Phase I Trial of Intravesical Nanoparticle Albumin-Bound Paclitaxel in the Treatment of Bacillus Calmette-Guérin Refractory Nonmuscle Invasive Bladder Cancer
James M. McKiernan, LaMont J. Barlow, Melissa A. Laudano, Mark Jonathan Mann, Daniel Peter Petrylak, Mitchell C. Benson · 2011 · The Journal of Urology
Current Indications for Chemotherapy in Prostate Cancer Patients
Fabio Calabrò, Cora Nanette Sternberg · 2006 · European Urology
New Developments in the Medical Management of Prostate Cancer
Manish Kohli, Donald J. Tindall · 2009 · Mayo Clinic Proceedings
An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions
Hai-Liang Zhang, Xiao-Jian Qin, Dalong Cao, Yao Zhu, Xu-Dong Yao, Shi-Lin Zhang, Bo Dai, Dingwei Ye · 2013 · Asian Journal of Andrology
Capitalizing on competition: An evolutionary model of competitive release in metastatic castration resistant prostate cancer treatment
Jeffrey West, Yongqian Ma, Paul K. Newton · 2018 · Journal of Theoretical Biology
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer
Carlo Cattrini, Elena Castro, Rebeca Lozano Mejorada, Elisa Zanardi, ALESSANDRA RUBAGOTTI, Francesco Boccardo, David Olmos · 2019 · Cancers
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
Dorff, Tanya, Horvath, Lisa G., Autio, Karen, Bernard-Tessier, Alice, Rettig, Matthew B., Machiels, Jean-Pascal, Bilen, Mehmet A., Lolkema, Martijn P., Adra, Nabil, Rottey, Sylvie et al. · 2024 · Clinical Cancer Research
Patient-reported Outcomes in Randomised Controlled Trials of Prostate Cancer: Methodological Quality and Impact on Clinical Decision Making
Fabio Efficace, Michael A. Feuerstein, Peter M. Fayers, Valentina Cafaro, James Andrew Eastham, Andrea L. Pusic, Jane M. Blazeby · 2013 · European Urology
Epothilones in the treatment of cancer
James Larkin, Stan B. Kaye · 2006 · Expert Opinion on Investigational Drugs
The Role of Hypoxia-Inducible Factor 1α in Determining the Properties of Castrate-Resistant Prostate Cancers
Weranja K. B. Ranasinghe, Lin Xiao, Suzana Kovac, Mike S. S. Chang, Carine Michiels, Damien Michael Bolton, Arthur Shulkes, Graham S. Baldwin, Oneel Patel · 2013 · PLoS ONE
Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program
Oliver A. Sartor, Nicholas J. Vogelzang, Christopher J. Sweeney, Daniel C. Fernandez, Fábio Almeida, Andrei H. Iagaru, Alan S. Brown, Matthew R. Smith, Manish Agrawal, Adam Paul Dicker et al. · 2017 · The Oncologist
Metastatic castration‐sensitive prostate cancer: Abiraterone, docetaxel, or…
Pedro Coelho Barata, Oliver A. Sartor · 2019 · Cancer
Hormone Refractory Prostate Cancer (Hrpc): Present and Future Approaches of Therapy
Giuseppe Di Lorenzo, Sabino De Placido · 2006 · International Journal of Immunopathology and Pharmacology
A Randomised Phase 2 Study Combining LY2181308 Sodium (Survivin Antisense Oligonucleotide) with First-line Docetaxel/Prednisone in Patients with Castration-resistant Prostate Cancer
Paweł Wiechno, Bradley G. Somer, Begoña Mellado, Piotr L Chłosta, José Manuel Cervera Grau, Daniel Castellano, Christoph W. Reuter, Michael Stöckle, Jörn Kamradt, Joanna Pikiel et al. · 2013 · European Urology
Targeted therapeutic approaches for hormone-refractory prostate cancer
Flora Stavridi, Eleni M. Karapanagiotou, Kostas Syrigos · 2010 · Cancer Treatment Reviews
Risk of Incremental Toxicities and Associated Costs of New Anticancer Drugs: A Meta-Analysis
Saroj Niraula, Eitan Amir, Francisco Vera-Badillo, Boštjan Šeruga, Alberto Ocaña, Ian F. Tannock · 2014 · Journal of Clinical Oncology
Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer
Pier‐Luc Clermont, Francesco Crea, Yan Ting Chiang, Dong Lin, Amy Xin Wei Zhang, James Z. L. Wang, Abhijit Parolia, Rebecca Chung‐Fern Wu, Hui Xue, Yuwei Wang et al. · 2016 · Clinical Epigenetics
Aberrant expression of CITED2 promotes prostate cancer metastasis by activating the nucleolin-AKT pathway
Seung-Hyun Shin, Ga Young Lee, Mingyu Lee, Jengmin Kang, Hyun‐Woo Shin, Yang‐Sook Chun, Jong‐Wan Park · 2018 · Nature Communications
Emerging Therapies to Prevent Skeletal Morbidity in Men With Prostate Cancer
Philip James Saylor, Richard J. Lee, Matthew R. Smith · 2011 · Journal of Clinical Oncology
Molecular Mechanisms and Bioavailability of Polyphenols in Prostate Cancer
Teodora Costea, Péter Nagy, Constanţa Ganea, János Szöllõsi, Maria‐Magdalena Mocanu · 2019 · International Journal of Molecular Sciences
Accelerating precision medicine in metastatic prostate cancer
Joaquı́n Mateo, Rana R. McKay, Wassim M. Abida, Rahul Raj Aggarwal, Joshi J. Alumkal, Ajjai Shivaram Alva, Felix Yi-Chung Feng, Xin Yuan Gao, Julie Nicole Graff, Maha Hussain et al. · 2020 · Nature Cancer
Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Ivan Henriquez, Mack Roach, Todd Matthew Morgan, Alberto Bossi, Junior Gómez, Oscar Abuchaibe, Felipe Couñago · 2021 · Biomedicines
Transforming growth factor-beta (TGF-β) in prostate cancer: A dual function mediator?
Sepideh Mirzaei, Mahshid Deldar Abad Paskeh, Yalda Saghari, Ali Zarrabi, Michael Richard Hamblin, Maliheh Entezari, Mehrdad Hashemi, Amir Reza Aref, Kiavash Hushmandi, Alan Prem Kumar et al. · 2022 · International Journal of Biological Macromolecules
A Randomized Phase 1 Study of Testosterone Replacement for Patients with Low-Risk Castration-Resistant Prostate Cancer
Russell Zelig Szmulewitz, Supriya Gupta Mohile, Edwin M. Posadas, Rangesh Kunnavakkam, Theodore G Karrison, Elizabeth Manchen, Walter Michael Stadler · 2009 · European Urology
Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: A review of their discovery, development, and place in therapy
Jacques-Pierre Moreau, Patrick Delavault, Joëlle Blumberg · 2006 · Clinical Therapeutics
Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
Gerhardt Attard, Debashis Sarker, Alison H. M. Reid, R. Molife, Chris C. Parker, Johann Sebastian De Bono · 2006 · British Journal of Cancer
Taxanes: promising anti-cancer drugs.
Nilufer Jasmine Selimah Fauzee · 2011 · PubMed
The Winning Formulation: The Development of Paclitaxel in Pancreatic Cancer
Wen Wee Ma, Manuel M. Hidalgo · 2013 · Clinical Cancer Research
PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy
Jin Zeng, Wei Liu, Yizeng Fan, Dalin He, Lei Li · 2017 · Theranostics
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry
Edoardo Francini, Kathryn P. Gray, Grace Shaw, Carolyn P. Evan, Anis Hamid, Caitlin Perry, Philip W. Kantoff, Mary‐Ellen Taplin, Christopher J. Sweeney · 2019 · Prostate Cancer and Prostatic Diseases
Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer
Leigh Ellis, Sheng‐Yu Ku, Swathi Ramakrishnan, Elena Lasorsa, Gizzou Azabdaftari, Alejandro Godoy, Роберто Пили · 2013 · Oncotarget
Navigating the evolving therapeutic landscape in advanced prostate cancer
Elward David Crawford, Daniel Peter Petrylak, Oliver A. Sartor · 2017 · Urologic Oncology Seminars and Original Investigations
AICAR Induces Apoptosis and Inhibits Migration and Invasion in Prostate Cancer Cells Through an AMPK/mTOR-Dependent Pathway
Chia‐Cheng Su, Kun-Lin Hsieh, Shu-Chi Wang, Hsin‐Chih Yeh, Shu‐Pin Huang, Po‐Len Liu, Shih-Hua Fang, Wei-Chung Cheng, Kuan-Hua Huang, Fang‐Yen Chiu et al. · 2019 · International Journal of Molecular Sciences
Randomized phase II study of danusertib in patients with metastatic castration‐resistant prostate cancer after docetaxel failure
Hielke J. Meulenbeld, Jean Pierre Bleuse, Elio M. Vinci, Éric Raymond, Giordano Vitali, Armando Santoro, Luigi Dogliotti, Rossana Berardi, Federico Cappuzzo, Scott T. Tagawa et al. · 2012 · British Journal of Urology
Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA)
Sachin S. Chandran, Sangeeta Ray Banerjee, Ron C. Mease, Martin G. Pomper, Samuel Ray Denmeade · 2008 · Cancer Biology & Therapy
Chemotherapy- and Irradiation-Induced Bone Loss in Adults with Solid Tumors
Michel D. Wissing · 2015 · Current Osteoporosis Reports
Methylseleninic Acid Enhances Taxane Drug Efficacy against Human Prostate Cancer and Down-Regulates Antiapoptotic Proteins Bcl-XL and Survivin
Hongbo Hu, Guang-Xun Li, Lei Wang, Jennifer C. Watts, Gerald F. Combs, Junxuan Lü · 2008 · Clinical Cancer Research
Persistent androgen receptor addiction in castration-resistant prostate cancer
Michael Thomas Schweizer, Evan Y. Yu · 2015 · Journal of Hematology & Oncology
Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing Twist
D Ruan, Jinrong He, Chien‐Feng Li, H-J Lee, J Liu, H-K Lin, Chia‐Hsin Chan · 2017 · Oncogene
Prostate Cancer: A Practical Approach to Current Management of Recurrent Disease
J Walczak, Michael Anthony Carducci · 2007 · Mayo Clinic Proceedings
CD44 regulates prostate cancer proliferation, invasion and migration via PDK1 and PFKFB4
Wei Li, Qian Li, Junhao Lin, Guihai Huang, Nan Hao, Xiuwang Wei, Wei Wang, Jianbo Liang · 2017 · Oncotarget
Recommandations françaises du Comité de cancérologie de l’AFU – actualisation 2020–2022 : cancer de la prostate
François Rozet, Pierre Mongiat-Artus, Christophe Hennequin, Jean‐Baptiste Beauval, Philippe Beuzeboc, Luc Cormier, Gaëlle Fromont, Romain Mathiéu, Guillaume Ploussard, Raphaële Renard‐Penna et al. · 2020 · The French Journal of Urology
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
Bishal Gyawali, Elisabeth G.E. de Vries, Urania G. Dafni, Teresa Maria Santos Amaral, Jorge Barriuso, Jan Bogaerts, Antonio Calles, Giuseppe Curigliano, Carlos Gomez‐Roca, Barbara Kiesewetter et al. · 2021 · ESMO Open
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study
Evan Y. Yu, Josep Maria Piulats, Gwénaëlle Gravis, Peter C.C. Fong, Tilman Todenhöfer, Brigitte Laguerre, José Ángel Arranz, Stéphane Marie. Oudard, Christophe Massard, Julia Heinzelbecker et al. · 2022 · European Urology
The role of proteomics in prostate cancer research: Biomarker discovery and validation
Elisa Pin, Claudia Fredolini, Emanuel F. Petricoin · 2012 · Clinical Biochemistry
The Impact of an Outpatient Palliative Care Consultation on Symptom Burden in Advanced Prostate Cancer Patients
Sriram Yennurajalingam, Bradley Atkinson, Jessica Masterson, David Shu-Cheong Hui, Diana L. Urbauer, Shi‐Ming Tu, Eduardo D Bruera · 2011 · Journal of Palliative Medicine
A phase II trial of gefitinib in patients with non‐metastatic hormone‐refractory prostate cancer
Eric Jay Small, Joseph A. Fontana, Nizar M. Tannir, Robert S. DiPaola, George Wilding, Mark A. Rubin, Renee Bailey Iacona, Fairooz F. Kabbinavar · 2007 · British Journal of Urology
Phase I/II Study of Bortezomib Plus Docetaxel in Patients with Advanced Androgen-Independent Prostate Cancer
Robert Dreicer, Daniel Peter Petrylak, David B. Agus, Iain James Webb, Bruce J. Roth · 2007 · Clinical Cancer Research
MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Gabriela Hernández‐Hoyos, Toddy Sewell, Robert Bader, Jeannette E. Bannink, Ruth A. Chenault, Mollie Daugherty, Maria Dasovich, Hang Fang, Rebecca J. Gottschalk, John Kumer et al. · 2016 · Molecular Cancer Therapeutics
The role of ketoconazole in current prostate cancer care
Vaibhav G. Patel, Bobby Chi-Hung Liaw, William K. Oh · 2018 · Nature Reviews Urology
Immunotherapy for prostate cancer: recent developments and future challenges
Michael Thomas Schweizer, Charles G. Drake · 2014 · Cancer and Metastasis Reviews
Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science
Nathan Coleman Nussbaum, Daniel J. George, Amy P. Abernethy, Chantal Dolan, Nina Oestreicher, Scott C. Flanders, Tanya Barauskas Dorff · 2016 · Prostate Cancer and Prostatic Diseases
CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer
Diogo Assed Bastos, Emmanuel S. Antonarakis · 2018 · Expert Review of Molecular Diagnostics
KLF5 downregulation desensitizes castration-resistant prostate cancer cells to docetaxel by increasing BECN1 expression and inducing cell autophagy
Jing Jia, Haibao Zhang, Qi Shi, Chao Yang, Jianbin Ma, Bin Jin, Xinyang Wang, Dalin He, Peng Guo · 2019 · Theranostics
Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer
Emmanuel S. Antonarakis, Andrew J. Armstrong · 2011 · Prostate Cancer and Prostatic Diseases
High-Throughput Transcriptomic and RNAi Analysis Identifies AIM1, ERGIC1, TMED3 and TPX2 as Potential Drug Targets in Prostate Cancer
Paula Vainio, John-Patrick Mpindi, Pekka J. Kohonen, Vidal Fey, Tuomas K. Mirtti, Kalle A. Alanen, Merja Perälä, Olli Kallioniemi, Kristiina Iljin · 2012 · PLoS ONE
Indium-111 capromab pendetide in the management of recurrent prostate cancer
Michael J. Manyak · 2008 · Expert Review of Anticancer Therapy
PSMA-mediated endosome escape-accelerating polymeric micelles for targeted therapy of prostate cancer and the real time tracing of their intracellular trafficking
Yajie Gao, Yanfang Li, Yushu Li, Lan Yuan, Yanxia Zhou, Jinwen Li, Lei Zhao, Chao Zhang, Xinru Li, Yan Liu · 2014 · Nanoscale
Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer
Patrick W. Sullivan, Parvez M Mulani, Mayer Fishman, Darryl J. Sleep · 2007 · Quality of Life Research
Overcoming Chemotherapy Resistance in Prostate Cancer
Ravi Amrit Madan, Sumanta Kumar Pal, Oliver A. Sartor, William L. Dahut · 2011 · Clinical Cancer Research
Serum/glucocorticoid‐regulated kinase 1 expression in primary human prostate cancers
Russell Zelig Szmulewitz, Elizabeth K. Chung, Hikmat A Al‐Ahmadie, Silver Daniel, Masha Kocherginsky, Aria A. Razmaria, Gregory P. Zagaja, Charles B. Brendler, Walter Michael Stadler, Suzanne Daniela Conzen · 2011 · The Prostate
GLI2 Knockdown Using an Antisense Oligonucleotide Induces Apoptosis and Chemosensitizes Cells to Paclitaxel in Androgen-Independent Prostate Cancer
Shintaro Narita, Alan So, Susan Ettinger, Norihiro Hayashi, Mototsugu Muramaki, Ladan Fazli, Young Soo Kim, Martin Edwin Gleave · 2008 · Clinical Cancer Research
Chemotherapy following radium‐223 dichloride treatment in ALSYMPCA
Oliver A. Sartor, Peter Hoskin, Robert Edward Coleman, Sten F. Nilsson, Nicholas J. Vogelzang, Oana Petrenciuc, Karin Staudacher, Marcus Thuresson, Chris C. Parker · 2016 · The Prostate
Current approaches to incorporation of radium-223 in clinical practice
Chris C. Parker, Axel Heidenreich, Sten F. Nilsson, Neal D. Shore · 2018 · Prostate Cancer and Prostatic Diseases
Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells
Kevin M. O’Connor, Catherine Gill, Matthias Tacke, F.-J.K. Rehmann, Katja A. Strohfeldt, Nigel J. Sweeney, John M. Fitzpatrick, R. William G. Watson · 2006 · APOPTOSIS
Imaging for Metastasis in Prostate Cancer: A Review of the Literature
Anthony Turpin, Edwina Girard, C. Baillet, Dominique Pasquier, Jonathan Olivier, Arnauld A. Villers, Philippe Puech, Nicolas Penel · 2020 · Frontiers in Oncology
First‐ and second‐line chemotherapy with docetaxel or mitoxantrone in patients with hormone‐refractory prostate cancer
Jorg Michels, Trina Montemurro, Nevin Murray, Christian Kollmannsberger, Kim Nguyen Chi · 2006 · Cancer
Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer
Patrick W. Sullivan, Joel B. Nelson, Parvez M Mulani, Darryl J. Sleep · 2006 · Quality of Life Research
Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy.
Rafał Turo, Samer Jallad, William Richard Cross, Stephen M. Prescott · 2013 · Canadian Urological Association Journal
Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials
Ryoichi Yano, Aya Konno, Kyohei Watanabe, Hitoshi Tsukamoto, Yuichiro Kayano, Hiroaki Ohnaka, Nobuyuki Goto, Toshiaki Nakamura, Mikio Masada · 2011 · International Journal of Clinical Oncology
Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone
Salvatore Luca Burgio, Vincenza Conteduca, Cecilia Menna, Elisa Carretta, Lorena Rossi, Emanuela Bianchi, Barbara Kopf, Francesca Fabbri, Dino Amadori, Ugo De Giorgi · 2014 · Endocrine Related Cancer
Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space
Oliver A. Sartor · 2011 · Journal of Hematology & Oncology
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
Lucy Heinemann, Guy R. Simpson, Angela Boxall, Timothy J. Kottke, Kate Relph, Richard G. Vile, Alan A. Melcher, Robin J D Prestwich, Kevin Joseph Harrington, Richard Morgan et al. · 2011 · BMC Cancer
Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting
Javier Puente, Enrique Grande, Ana Medina, Pablo Maroto, Núria Laínez, José Ángel Arranz · 2017 · Therapeutic Advances in Medical Oncology
PSA Flare With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer
Salvatore Luca Burgio, Vincenza Conteduca, Britt Rudnas, Francesco Carrozza, Enrico Campadelli, Emanuela Bianchi, Paolo Fabbri, Marco Montanari, Elisa Carretta, Cecilia Menna et al. · 2014 · Clinical Genitourinary Cancer
Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial
Karim S. Fizazi, Pablo González Mella, Daniel Castellano, José Nicolas Minatta, Arash Rezazadeh Kalebasty, David R. Shaffer, Juan Carlos Vázquez Limón, Héctor Manuel Sánchez López, Andrew J. Armstrong, Lisa Glen Horvath et al. · 2021 · European Journal of Cancer
Tumors That Acquire Resistance to Low-Dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide
Urban Emmenegger, Giulio Francia, Annabelle Chow, Yuval Shaked, Andrew Kouri, Shan Man, Robert S. Kerbel · 2011 · Neoplasia
Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms
Komal Raina, Rajesh Agarwal · 2007 · Acta Pharmacologica Sinica
Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy
Thomas Nelius, Tobias Klatte, Werner T. W. de Riese, Allan L. Haynes, Stéphanie Filleur · 2009 · Medical Oncology
Management of Frail and Not-Frail elderly cancer patients in a hospital-based geriatric oncology program
Umberto Basso, Singora Tonti, Catia Bassi, Antonella Brunello, Lara Maria Pasetto, Daniela Scaglione, Cristina Falci, Manuela Beda, Savina M. Luciana Aversa, Micaela Stefani et al. · 2008 · Critical Reviews in Oncology/Hematology
Oral Anticancer Drugs: How Limited Dosing Options and Dose Reductions May Affect Outcomes in Comparative Trials and Efficacy in Patients
Vinay K. Prasad, Paul R. Massey, Tito Fojo · 2014 · Journal of Clinical Oncology
Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15)
Gwénaëlle Gravis, Patricia Marino, Florence Joly, Stéphane Marie. Oudard, Franck Priou, Benjamin Esterni, I. Latorzeff, R. Delva, I. Krakowski, Brigitte Laguerre et al. · 2014 · European Journal of Cancer
Dose‐Dependent Therapeutic Distinction between Active and Passive Targeting Revealed Using Transferrin‐Coated PGMA Nanoparticles
Ruhani Singh, Marck Nörret, Michael J. House, Yuriy Galabura, Michael Bradshaw, Diwei Ho, Robert C. Woodward, Timothy G. St. Pierre, Igor A. Luzinov, Nicole M. Smith et al. · 2015 · Small
Functional reprogramming of human prostate cancer to promote local attraction of effector CD8+T cells
Ravikumar Muthuswamy, John M. Corman, Kathryn L. Dahl, Gurkamal S. Chatta, Paweł Kaliński · 2016 · The Prostate
Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells inhibits NK cell-mediated killing through LLT1-NKRP1A (CD161) interaction
Stephen O. Mathew, Pankaj Chaudhary, Sheila B. Powers, Jamboor K. Vishwanatha, Porunelloor Abraham Mathew · 2016 · Oncotarget